Biogen and Neomorph are teaming up to develop molecular glue breakers for Alzheimer's disease and more

WESTON (dpa-AFX) – Biogen Inc. (BIIB) and Neomorph Inc. have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s disease and rare neurological and immunological diseases.

As part of the collaboration, the companies plan to leverage Neomorph’s proprietary molecular adhesive discovery platform to accelerate the identification and validation of novel therapeutic small-molecule molecular adhesive degraders.

Under the terms of the agreement, Neomorph will receive an upfront payment and be eligible to receive conditional milestone payments per goal as the partnership progresses through its phases. These include certain preclinical milestones payable in the near term and certain clinical, regulatory, commercial and sales milestones expected to occur later this decade and beyond, for an aggregate amount of up to $1.45 billion.

Biogen will reimburse Neomorph for certain research and development costs. Neomorph is also eligible to receive potential future royalties in the mid-single digit to low double-digit range.

Related Posts

Der Enigma Code – Geheimsache Erfurt

Kick-off on Tuesday: So functional for the new Champions League mode

Driving four times faster than the police allow